UAE sends 300,000 vaccine doses to Comoros
ABU DHABI: The UAE has dispatched an aircrat carrying 9 metric tonnes of medical supplies and 300,000 doses of the COVID-19 vaccine to the Union of the Comoros to help curb the spread of the virus.
The aircrat was received at the airport of the Comorian capital, Moroni, by Azali Assoumani, President of the Union of the Comoros, and Saeed Al Maqbali, UAE Ambassador to the Comoros.
Assoumanicommendedtheuae’sglobalhumanitarian and developmental efforts, highlighting the UAE’S continuous support for his country, especially during the COVID-19 pandemic.
He also expressed his appreciation to the UAE’S leadership, government and people for their noble humanitarian stances and their support of the Comoros and its people.
For his part, Al Maqbali said, “This gesture is part of the UAE’S efforts to support the drive of Comoros’ government and medical sector in controlling the COVID-19 pandemic.”
The UAE Ambassador underscored the deep relations that the UAE and the Comoros share, and the keenness of their leaderships to grow and strengthen the ties between their countries.
USE OF SOTROVIMAB: The Ministry of Health and Prevention (MOHAP), in collaboration with the Department of Health - Abu Dhabi (DOH) and Dubai Health Authority (DHA), has recently announced the treatment results for anti-viral medicine Sotrovimab in treating mild to moderate COVID-19 cases among high-risk patients including adults, pregnant women and children aged 12 and above who are at risk of progressing to severe symptoms and meet other relevant criteria.
Themohaphasapprovedtheuseofsotrovimab, which is produced by global biopharmaceutical company Glaxosmithkline (GSK), ater conducting local evaluation. It has also been approved for emergency use by the US Food and Drug Administration.
Between 30 June and 13 July, Sotrovimab was administered to 6,175 patients with COVID-19 in Abu Dhabi. About 52 per cent of the patients were aged 50 or above, and almost all recipients had multiple comorbidities including obesity, cancer, cardiovascular disease and diabetes.
97 per cent of recipients fully recovered within 14 days. The medication also resulted in 100 per cent prevention of death among recipients and 99 per cent prevention of admission to ICU.
Sotrovimab is a monoclonal antibody treatment delivered through intravenous therapy in accordance with protocols developed by the National Scientific Commitee.